Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 73 Lung Neoplasms 64 Breast Neoplasms 63 Lymphoma 58 Ovarian Neoplasms 51 Leukemia 44 Sarcoma 43 Prostatic Neoplasms 39 Multiple Myeloma 36 Head and Neck Neoplasms 36 Central Nervous System Neoplasms 36 Squamous Cell Carcinoma of Head and Neck 32 Colorectal Neoplasms 31 Carcinoma, Ovarian Epithelial 30 Melanoma 29 Rectal Neoplasms 28 Neoplasm Metastasis 27 Uterine Cervical Neoplasms 26 Precursor Cell Lymphoblastic Leukemia-Lymphoma 26 Lymphoma, Large B-Cell, Diffuse 26 Brain Neoplasms 26 Urinary Bladder Neoplasms 24 Leukemia, Lymphocytic, Chronic, B-Cell 24 Leukemia, Myeloid, Acute 23 Fallopian Tube Neoplasms 23 Endometrial Neoplasms 22 Glioblastoma 21 Adenocarcinoma of Lung 21 Lymphoma, Mantle-Cell 18 Gliosarcoma 17

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NETWORK × Breast Cancer Invasive Nos × Clear all

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡